![Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT - The Lancet Diabetes & Endocrinology Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/6c920c9a-439e-427c-b5a4-d2dc4127d706/gr1_lrg.gif)
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT - The Lancet Diabetes & Endocrinology
![A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41436-020-01006-8/MediaObjects/41436_2020_1006_Fig1_HTML.png)
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine
![Patient disposition through the OLE. Abbreviations: IV, intravenous;... | Download Scientific Diagram Patient disposition through the OLE. Abbreviations: IV, intravenous;... | Download Scientific Diagram](https://www.researchgate.net/publication/343976200/figure/fig1/AS:983795817795586@1611566609274/Patient-disposition-through-the-OLE-Abbreviations-IV-intravenous-OLE-open-label.png)